메뉴 건너뛰기




Volumn 14, Issue 5, 2008, Pages 640-655

Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study

Author keywords

Disease modifying therapies; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB;

EID: 46849118240     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507086463     Document Type: Article
Times cited : (21)

References (59)
  • 2
    • 0033994836 scopus 로고    scopus 로고
    • MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b
    • Richert, ND, Zierak, MC, Bash, CN, Lewis, BK, McFarland, HF, Frank, JA. MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b. Mult Scler 2000; 6:86-90.
    • (2000) Mult Scler , vol.6 , pp. 86-90
    • Richert, N.D.1    Zierak, M.C.2    Bash, C.N.3    Lewis, B.K.4    McFarland, H.F.5    Frank, J.A.6
  • 3
    • 0030054701 scopus 로고    scopus 로고
    • Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: Disease activity resumes after stopping treatment
    • Durelli, L, Bongioanni, MR, Ferrero, B, Ferri, R, Imperiale, D, Bradac, GB, et al. Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment. Neurology 1996; 47: 123-129.
    • (1996) Neurology , vol.47 , pp. 123-129
    • Durelli, L.1    Bongioanni, M.R.2    Ferrero, B.3    Ferri, R.4    Imperiale, D.5    Bradac, G.B.6
  • 4
    • 0033596756 scopus 로고    scopus 로고
    • Interferon-alpha 2a reduces MRI disease activity in relapsing-remitting multiple sclerosis
    • Myhr, KM, Riise, T, Lilleas, FEG, Beiske, TG, Celius, EG, Edland, A, et al. Interferon-alpha 2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Neurology 1999; 52: 1049-1056.
    • (1999) Neurology , vol.52 , pp. 1049-1056
    • Myhr, K.M.1    Riise, T.2    Lilleas, F.E.G.3    Beiske, T.G.4    Celius, E.G.5    Edland, A.6
  • 5
    • 0037154192 scopus 로고    scopus 로고
    • Disease-modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
    • Goodin, DS, Frohman, EM, Garmany, GP, Halper, J, Likosky, WH, Lublin, FD, et al. Disease-modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-178.
    • (2002) Neurology , vol.58 , pp. 169-178
    • Goodin, D.S.1    Frohman, E.M.2    Garmany, G.P.3    Halper, J.4    Likosky, W.H.5    Lublin, F.D.6
  • 6
    • 0036191577 scopus 로고    scopus 로고
    • Freedman, MS, Blumhardt, LD, Brochet, B, Comi, G, Noseworthy, JH, Sandberg-Wolheim, M, et al. and the Paris Workshop Group. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler 2002; 8: 19-23.
    • Freedman, MS, Blumhardt, LD, Brochet, B, Comi, G, Noseworthy, JH, Sandberg-Wolheim, M, et al. and the Paris Workshop Group. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler 2002; 8: 19-23.
  • 8
    • 3042686293 scopus 로고    scopus 로고
    • Effect of drugs in secondary disease progression in patients with multiple sclerosis
    • Kappos, L. Effect of drugs in secondary disease progression in patients with multiple sclerosis. Mult Scler 2004; 10: S46-S55.
    • (2004) Mult Scler , vol.10
    • Kappos, L.1
  • 9
    • 0036017494 scopus 로고    scopus 로고
    • Disability and treatment patterns of multiple sclerosis patients in United States: A comparison of veterans and non-veterans
    • Vollmer, TL, Hadjimichael, O, Preiningerova, J, Ni, W, Buenconsejo, J. Disability and treatment patterns of multiple sclerosis patients in United States: a comparison of veterans and non-veterans. J Rehabil Res Dev 2002; 39: 163-174.
    • (2002) J Rehabil Res Dev , vol.39 , pp. 163-174
    • Vollmer, T.L.1    Hadjimichael, O.2    Preiningerova, J.3    Ni, W.4    Buenconsejo, J.5
  • 10
    • 13844306541 scopus 로고    scopus 로고
    • Treatment patterns of multiple sclerosis patients: A comparison of veterans and non-veterans using the NARCOMS registry
    • Lo, A, Hadjimichael, O, Vollmer, TL. Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry. Mult Scler 2005; 11: 33-40.
    • (2005) Mult Scler , vol.11 , pp. 33-40
    • Lo, A.1    Hadjimichael, O.2    Vollmer, T.L.3
  • 11
    • 46849088263 scopus 로고    scopus 로고
    • Changing therapy in relapsing multiple sclerosis: Considerations and recommendations of a task force of the National Multiple Sclerosis Society
    • Accessed 13 January 2007 at
    • National Multiple Sclerosis Society. Changing therapy in relapsing multiple sclerosis: considerations and recommendations of a task force of the National Multiple Sclerosis Society. Treatment recommendations for physicians, Expert opinion paper, Medical Advisory Board, 2005. Accessed 13 January 2007 at: http://www.nationalmssociety.org/pdf/ forpros/Exp_ChangTherapy.pdf.
    • Treatment recommendations for physicians, Expert opinion paper, Medical Advisory Board, 2005
  • 12
    • 0032438047 scopus 로고    scopus 로고
    • Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a
    • Mohr, DC, Likosky, W, Boudewyn, A, Marietta, P, Dwyer, P, Van Der Wende, J. et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler 1998; 4: 487-489.
    • (1998) Mult Scler , vol.4 , pp. 487-489
    • Mohr, D.C.1    Likosky, W.2    Boudewyn, A.3    Marietta, P.4    Dwyer, P.5    Van Der Wende, J.6
  • 13
    • 20144382021 scopus 로고    scopus 로고
    • Factors related with treatment adherence to interferon β and glatiramer acetate therapy in multiple sclerosis
    • Rio, J, Porcel, J, Tellez, N, Sanchez-Betancourt, A, Tintore, M, Arevalo, MJ, et al. Factors related with treatment adherence to interferon β and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005; 11: 306-309.
    • (2005) Mult Scler , vol.11 , pp. 306-309
    • Rio, J.1    Porcel, J.2    Tellez, N.3    Sanchez-Betancourt, A.4    Tintore, M.5    Arevalo, M.J.6
  • 14
    • 20044388168 scopus 로고    scopus 로고
    • Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone)
    • Haas, J, Firzlaff, M. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 2005; 12: 425-431.
    • (2005) Eur J Neurol , vol.12 , pp. 425-431
    • Haas, J.1    Firzlaff, M.2
  • 15
    • 0042932742 scopus 로고    scopus 로고
    • Interrupted therapy: Stopping and switching of the beta-interferons prescribed for MS
    • Tremlett, HL, Oger, J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 61: 551-554.
    • (2003) Neurology , vol.61 , pp. 551-554
    • Tremlett, H.L.1    Oger, J.2
  • 16
    • 0030332317 scopus 로고
    • Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: Relationship to adherence to treatment
    • Mohr, DC, Goodkin, DE, Likosky, W, Gatto, N, Neilley, LK, Griffin, C, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 1966; 2: 222-226.
    • (1966) Mult Scler , vol.2 , pp. 222-226
    • Mohr, D.C.1    Goodkin, D.E.2    Likosky, W.3    Gatto, N.4    Neilley, L.K.5    Griffin, C.6
  • 17
    • 33744808980 scopus 로고    scopus 로고
    • on behalf of the Danish Multiple Sclerosis Study Group. Immunomodulatory treatment of multiple sclerosis in Denmark: A prospective nationwide study
    • Sorensen, PS, Koch-Henriksen, N, Ravnborg, M, Frederiksen, JL, Jensen, K, Heltberg, A, et al. on behalf of the Danish Multiple Sclerosis Study Group. Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide study. Mult Scler 2006; 12: 253-264.
    • (2006) Mult Scler , vol.12 , pp. 253-264
    • Sorensen, P.S.1    Koch-Henriksen, N.2    Ravnborg, M.3    Frederiksen, J.L.4    Jensen, K.5    Heltberg, A.6
  • 19
    • 0041372590 scopus 로고    scopus 로고
    • Adherence to IFNβ therapy in multiple sclerosis: An Italian clinical setting
    • Taus, C, Taffi, R, Morelli, M, Fie, A, Angeled, VA, Sgolastra, M, et al. Adherence to IFNβ therapy in multiple sclerosis: an Italian clinical setting. Mult Scler 2001; 7: S18-S128.
    • (2001) Mult Scler , vol.7
    • Taus, C.1    Taffi, R.2    Morelli, M.3    Fie, A.4    Angeled, V.A.5    Sgolastra, M.6
  • 20
    • 13844315516 scopus 로고    scopus 로고
    • Stopping beta-interferon therapy in multiple sclerosis: An analysis of stopping patterns
    • O'Rourke, KET, Hutchinson, M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005; 11: 46-50.
    • (2005) Mult Scler , vol.11 , pp. 46-50
    • O'Rourke, K.E.T.1    Hutchinson, M.2
  • 21
    • 0036835959 scopus 로고    scopus 로고
    • A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta
    • Paolillo, A, Pozzillia, C, Giugnia, E, Tomassinia, V, Gasperini, C, Fiorellia, M, et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta. Eur J Neurol 2002; 9: 645-655.
    • (2002) Eur J Neurol , vol.9 , pp. 645-655
    • Paolillo, A.1    Pozzillia, C.2    Giugnia, E.3    Tomassinia, V.4    Gasperini, C.5    Fiorellia, M.6
  • 22
    • 33846298073 scopus 로고    scopus 로고
    • Long-term emotional state of multiple sclerosis patients treated with interferon beta
    • Porcel, J, Rio, J, Sanchez-Betancourt, A, Arevalo, MJ, Tintore, M, Tellez, N, et al. Long-term emotional state of multiple sclerosis patients treated with interferon beta. Mult Scler 2006; 12: 802-807.
    • (2006) Mult Scler , vol.12 , pp. 802-807
    • Porcel, J.1    Rio, J.2    Sanchez-Betancourt, A.3    Arevalo, M.J.4    Tintore, M.5    Tellez, N.6
  • 23
    • 0348012903 scopus 로고    scopus 로고
    • the North Italy Multiple Sclerosis Group. A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: Different response in drop-outs and treated patients
    • Milanese, C, La Mantia, L, Palumbo, R, Martinelli, V, Murialdo, A, Zaffaroni, M, et al. the North Italy Multiple Sclerosis Group. A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003; 74: 1689-1692.
    • (2003) J Neurol Neurosurg Psychiatry , vol.74 , pp. 1689-1692
    • Milanese, C.1    La Mantia, L.2    Palumbo, R.3    Martinelli, V.4    Murialdo, A.5    Zaffaroni, M.6
  • 24
  • 25
    • 0035525120 scopus 로고    scopus 로고
    • Adherence to disease-modifying therapy in multiple sclerosis: Part II
    • Holland, N, Wiesel, P, Cavallo, P, Edwards, C, Halper, J, Kalb, R, et al. Adherence to disease-modifying therapy in multiple sclerosis: Part II. Rehabil Nurs 2001; 26: 221-226.
    • (2001) Rehabil Nurs , vol.26 , pp. 221-226
    • Holland, N.1    Wiesel, P.2    Cavallo, P.3    Edwards, C.4    Halper, J.5    Kalb, R.6
  • 26
    • 0348223726 scopus 로고    scopus 로고
    • Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment
    • Bayas, A, Gold, R. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment. J Neurol 2003; 250: IV3-IV8.
    • (2003) J Neurol , vol.250
    • Bayas, A.1    Gold, R.2
  • 27
    • 0033980617 scopus 로고    scopus 로고
    • Managing the adverse effects of interferon-β therapy in multiple sclerosis
    • Bayas, A, Rieckmann, P. Managing the adverse effects of interferon-β therapy in multiple sclerosis. Drug Safety 2000; 22: 149-159.
    • (2000) Drug Safety , vol.22 , pp. 149-159
    • Bayas, A.1    Rieckmann, P.2
  • 28
    • 0029948580 scopus 로고    scopus 로고
    • Lublin, FD, Whitaker, JN, Eidelman, BH, Miller, AE, Arnason, BG, Burks, JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996; 46: 12-18.
    • Lublin, FD, Whitaker, JN, Eidelman, BH, Miller, AE, Arnason, BG, Burks, JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996; 46: 12-18.
  • 29
    • 51849093444 scopus 로고    scopus 로고
    • Importance of adherence to and persistence with prescribed treatments in patients with multiple sclerosis
    • Munschauer, FE, Weinstock-Guttman, B. Importance of adherence to and persistence with prescribed treatments in patients with multiple sclerosis. Business briefing: U S Neurology Review 2005; 1-5.
    • (2005) Business briefing: U S Neurology Review , pp. 1-5
    • Munschauer, F.E.1    Weinstock-Guttman, B.2
  • 30
    • 10344225070 scopus 로고    scopus 로고
    • Strategies for managing the side effects of treatments for multiple sclerosis
    • Langer-Gould, A, Moses, HH, Murray, TJ. Strategies for managing the side effects of treatments for multiple sclerosis. Neurology 2004; 63: S35-S41.
    • (2004) Neurology , vol.63
    • Langer-Gould, A.1    Moses, H.H.2    Murray, T.J.3
  • 31
    • 22144451484 scopus 로고    scopus 로고
    • Factors leading patients to discontinue multiple sclerosis therapies
    • Daugherty, KK, Butler, JS, Mattingly, M, Ryan, M. Factors leading patients to discontinue multiple sclerosis therapies. J Am Pharm Assoc 2005; 45: 371-375.
    • (2005) J Am Pharm Assoc , vol.45 , pp. 371-375
    • Daugherty, K.K.1    Butler, J.S.2    Mattingly, M.3    Ryan, M.4
  • 33
    • 0035018884 scopus 로고    scopus 로고
    • Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject
    • Mohr, DC, Boudewyn, AC, Likosky, W, Levine, E, Goodkin, DE. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001; 23: 125-132.
    • (2001) Ann Behav Med , vol.23 , pp. 125-132
    • Mohr, D.C.1    Boudewyn, A.C.2    Likosky, W.3    Levine, E.4    Goodkin, D.E.5
  • 34
    • 0033754634 scopus 로고    scopus 로고
    • Multiple sclerosis, disease-modifying treatments and depression: A critical methodological review
    • Feinstein, A. Multiple sclerosis, disease-modifying treatments and depression: a critical methodological review. Mult Scler 2000; 6: 343-348.
    • (2000) Mult Scler , vol.6 , pp. 343-348
    • Feinstein, A.1
  • 35
    • 0030912908 scopus 로고    scopus 로고
    • Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis
    • Mohr, DC, Goodkin, DE, Likosky, W, Gatto, N, Baumann, KA, Rudick, RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997; 54: 531-533.
    • (1997) Arch Neurol , vol.54 , pp. 531-533
    • Mohr, D.C.1    Goodkin, D.E.2    Likosky, W.3    Gatto, N.4    Baumann, K.A.5    Rudick, R.A.6
  • 36
    • 0032874014 scopus 로고    scopus 로고
    • Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis
    • Mohr, DC, Likosky, W, Dwyer, P, Van Der Wende, J, Boudewyn, AC, Goodkin, DE. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis. Arch Neurol 1999; 56: 1263-1265.
    • (1999) Arch Neurol , vol.56 , pp. 1263-1265
    • Mohr, D.C.1    Likosky, W.2    Dwyer, P.3    Van Der Wende, J.4    Boudewyn, A.C.5    Goodkin, D.E.6
  • 37
    • 0038149171 scopus 로고    scopus 로고
    • Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis
    • Fraser, C, Hadjimichael, O, Vollmer, T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nurs 2003; 35: 163-170.
    • (2003) J Neurosci Nurs , vol.35 , pp. 163-170
    • Fraser, C.1    Hadjimichael, O.2    Vollmer, T.3
  • 38
    • 0035486933 scopus 로고    scopus 로고
    • Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting MS
    • Fraser, C, Hadjimichael, O, Vollmer, T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting MS. J Neurosci Nurs 2001; 33: 231-239.
    • (2001) J Neurosci Nurs , vol.33 , pp. 231-239
    • Fraser, C.1    Hadjimichael, O.2    Vollmer, T.3
  • 39
    • 0033544299 scopus 로고    scopus 로고
    • Side effects of interferon beta therapy and their management
    • Walther, E, Hohlfeld, R. Side effects of interferon beta therapy and their management. Neurology 1999; 53: 1622-1627.
    • (1999) Neurology , vol.53 , pp. 1622-1627
    • Walther, E.1    Hohlfeld, R.2
  • 40
    • 0033754825 scopus 로고    scopus 로고
    • Interferon-beta treatment for patients with multiple sclerosis: The patients' perceptions of the side-effects
    • Gottberg, K, Gardulf, A, Fredrikson, S. Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects. Mult Scler 2000; 6: 349-354.
    • (2000) Mult Scler , vol.6 , pp. 349-354
    • Gottberg, K.1    Gardulf, A.2    Fredrikson, S.3
  • 41
    • 32544452724 scopus 로고    scopus 로고
    • Current issues in immunomodulatory treatment of multiple sclerosis. A practical approach
    • Stangel, M, Gold, R, Gass, A, Haas, J, Jung, S, Elias, W, et al. Current issues in immunomodulatory treatment of multiple sclerosis. A practical approach. J Neurol 2006; 253:I/32-I/36.
    • (2006) J Neurol , vol.253
    • Stangel, M.1    Gold, R.2    Gass, A.3    Haas, J.4    Jung, S.5    Elias, W.6
  • 42
    • 31644434217 scopus 로고    scopus 로고
    • The Sonya Slifka Longitudinal Multiple Sclerosis Study: Methods and sample characteristics
    • Minden, SL, Frankel, D, Hadden, L, Perloff, J, Srinath, KP, Hoaglin, DC. The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler 2006; 12: 24-38.
    • (2006) Mult Scler , vol.12 , pp. 24-38
    • Minden, S.L.1    Frankel, D.2    Hadden, L.3    Perloff, J.4    Srinath, K.P.5    Hoaglin, D.C.6
  • 43
    • 0020686503 scopus 로고
    • New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
    • Poser, CM, Paty, DW, Scheinberg, L, McDonald, I, Davis, FA, Ebers, GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
    • (1983) Ann Neurol , vol.13 , pp. 227-231
    • Poser, C.M.1    Paty, D.W.2    Scheinberg, L.3    McDonald, I.4    Davis, F.A.5    Ebers, G.C.6
  • 44
    • 46849104186 scopus 로고    scopus 로고
    • Accessed 19 October 2006 at
    • US Census Bureau. Accessed 19 October 2006 at: http://www.census.gov/.
  • 45
    • 0003750767 scopus 로고    scopus 로고
    • home page. Accessed 29 October 2006 at
    • US Census Bureau. Current Population Survey home page. Accessed 29 October 2006 at: http://www.census.gov/cps/.
    • Current Population Survey
  • 46
    • 46849111895 scopus 로고    scopus 로고
    • MEPS, Accessed 19 October 2006 at
    • Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey (MEPS). Accessed 19 October 2006 at: http://www.meps.ahrq.gov/.
  • 47
    • 0003864799 scopus 로고    scopus 로고
    • Accessed 19 October 2006 at
    • National Center for Health Statistics. National Health Interview Survey. Accessed 19 October 2006 at: http://www.cdc.gov/nchs/nhis.htm.
    • National Health Interview Survey
  • 48
    • 0020841184 scopus 로고
    • The structure of psychological distress and well-being in general populations
    • Veit, CT, Ware, JE. The structure of psychological distress and well-being in general populations. J Consult Clin Psychol 1983; 51: 730-742
    • (1983) J Consult Clin Psychol , vol.51 , pp. 730-742
    • Veit, C.T.1    Ware, J.E.2
  • 49
    • 0028817189 scopus 로고
    • Disease steps in multiple sclerosis: A simple approach to evaluate disease progression
    • Hohol, MJ, Orav, EJ, Weiner, HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 1995; 45: 251-255.
    • (1995) Neurology , vol.45 , pp. 251-255
    • Hohol, M.J.1    Orav, E.J.2    Weiner, H.L.3
  • 50
    • 0029913882 scopus 로고    scopus 로고
    • Defining the course of multiple sclerosis: Results of an international survey
    • Lublin, FD, Reingold, SC. Defining the course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-911.
    • (1996) Neurology , vol.46 , pp. 907-911
    • Lublin, F.D.1    Reingold, S.C.2
  • 51
    • 46849119105 scopus 로고    scopus 로고
    • Record of physicians' activities (PPA questionnaire)
    • Chicago, IL: American Medical Association
    • Randolph, L. Record of physicians' activities (PPA questionnaire). Physician Characteristics and Distribution in the U.S. Chicago, IL: American Medical Association, 1997.
    • (1997) Physician Characteristics and Distribution in the U.S
    • Randolph, L.1
  • 52
    • 46849103964 scopus 로고    scopus 로고
    • American Board of Medical Specialists. Accessed 15 December 2006 at
    • American Board of Medical Specialists. Accessed 15 December 2006 at: http://www.abms.org/.
  • 53
    • 46849117631 scopus 로고    scopus 로고
    • Accessed 19 October 2006 at
    • AMA DoctorFinder. Accessed 19 October 2006 at: http://webapps.ama-assn.org/doctorfinder/home.html?aps/amahg.htm.
  • 54
    • 46849101135 scopus 로고    scopus 로고
    • Getting disease-modifying drugs in the U.S
    • Northrop, D. Getting disease-modifying drugs in the U.S. Inside MS 2002; 20 (3).
    • (2002) Inside MS , vol.20 , Issue.3
    • Northrop, D.1
  • 55
    • 34249108301 scopus 로고    scopus 로고
    • Access to health care for people with multiple sclerosis
    • Minden, SL, Frankel, D, Hadden, L, Hoaglin, DC. Access to health care for people with multiple sclerosis. Mult Scler 2007; 13: 547-558.
    • (2007) Mult Scler , vol.13 , pp. 547-558
    • Minden, S.L.1    Frankel, D.2    Hadden, L.3    Hoaglin, D.C.4
  • 57
    • 0034992601 scopus 로고    scopus 로고
    • Axonal and neuronal degeneration in multiple sclerosis: Mechanisms and functional consequences
    • Bjartmar, C, Trapp, BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001; 14: 271-278.
    • (2001) Curr Opin Neurol , vol.14 , pp. 271-278
    • Bjartmar, C.1    Trapp, B.D.2
  • 58
    • 9744248302 scopus 로고    scopus 로고
    • Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis
    • Heesen, C, Kasper, J, Segal, J, Kopke, S, Muhlhauser, I. Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis. Mult Scler 2004; 10: 643-650.
    • (2004) Mult Scler , vol.10 , pp. 643-650
    • Heesen, C.1    Kasper, J.2    Segal, J.3    Kopke, S.4    Muhlhauser, I.5
  • 59
    • 0004012988 scopus 로고
    • Multiple sclerosis: A statistical portrait. A compendium of data on demographics, disability, and health services utilization in the United States
    • August
    • Minden, SL, Marder, WD, Harrold, LN, Dor, A. Multiple sclerosis: a statistical portrait. A compendium of data on demographics, disability, and health services utilization in the United States. Report to the National Multiple Sclerosis Society, August 1993.
    • (1993) Report to the National Multiple Sclerosis Society
    • Minden, S.L.1    Marder, W.D.2    Harrold, L.N.3    Dor, A.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.